546P - AVAPLUS: Impact of geriatric assessment on first-line treatment duration (TD) and progression free survival (PFS) in mCRC patients ≥ 70 years

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Gastrointestinal Cancers
Presenter Lore Decoster
Citation Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370
Authors L. Decoster1, C. Kenis2, B. Naessens3, G. Houbiers4, M. De Man5, G. Lambecht6, E. Monsaert7, V. Moons8, P. Vergauwe9, H. Prenen10, E. van Cutsem10, E. Beutels11, D. Frijns12, H. Wildiers2
  • 1Medical Oncology, UZ Brussel, 1090 - Brussels/BE
  • 2Medical Oncology, University Hospitals Leuven - Campus Gasthuisberg, Leuven/BE
  • 3Gastro-enterology, AZ Nikolaas Hospital, St Niklaas/BE
  • 4Gastro-enterology, Centre Hospitalier Chrétien (CHC), Liège/BE
  • 5Gastro-enterology, Gent University Hospital, Gent/BE
  • 6Gastro-enterology, AZ Damiaan, Oostende/BE
  • 7Gastro-enterology, AZ Maria Middelares, Gent/BE
  • 8Gastro-enterology, Imeldaziekenhuis, Bonheiden/BE
  • 9Gastro-enterology, AZ Groeninge Hospital, Kortrijk/BE
  • 10Gastro-enterology, University Hospitals Leuven - Campus Gasthuisberg, Leuven/BE
  • 11Medical Writing, Innosens, Brussels/BE
  • 12Medical Affairs, ROCHE NV/SA, Brussels/BE



Geriatric assessments (GA) allow evaluation of individual global health status and treatment optimisation. This real-life study complements the knowledge on chemotherapy (CT) and bevacizumab usage in elderly with mCRC focussing the impact of geriatric screening and GA on TD, PFS and severe toxicity.


This study included 252 Belgian mCRC patients ≥ 70 years receiving CT with or without bevacizumab. Eastern Cooperative Oncology Group (ECOG), geriatric screening with G8 and Flemish Triage Risk Screening Tool (fTRST), as well as GA including activities of daily living (ADL), instrumental activities of daily living (IADL), Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS), Mini Nutritional Assessment (MNA), Charlson Comorbidity Index (CCI), and Mobility-Tiredness Test (Mob-T) was performed in all patients at baseline. For correlations with the different screening and GA components, logrank tests (for TD and PFS), Wilcoxon or Student t-tests (for severe toxicity) and multivariate analyses were used. Additionally, a subgroup analysis excluding patients with ECOG ≥ 2 at baseline was performed.


Median TD (95% CI) was 5.5m (5.1-6.2) in the total safety population. In univariate analysis, ECOG > 1, which was only 14.6% of patients, and MNA were the only baseline parameters significantly associated with TD (p = 0.0006 and p = 0.0162, respectively), while G8 showed a trend (p = 0.0607). Significant correlations were observed for PFS vs. ECOG (p 


In older mCRC patients, ECOG is a strong predictive marker for treatment duration and PFS, mainly driven by patients with ECOG ≥ 2. In the large group of patients with ECOG ≤ 1, MNA is a predictive marker for PFS.

Clinical trial identification


Legal entity responsible for the study

Roche NV/SA Belgium


Roche NV/SA Belgium


All authors have declared no conflicts of interest.